Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia

Schizophrenia Research

Volumn 169, Issue 1-3, 2015, Pages 393-399

  Schreiner, Andreas ^a   Aadamsoo, Kaire ^b   Altamura, A Carlo ^c   Franco, Manuel ^d   Gorwood, Philip ^e   Neznanov, Nikolaj G ^f   Schronen, Juan ^g   Ucok, Alp ^h   Zink, Mathias ⁱ   Janik, Adam ^j   Cherubin, Pierre ^k   Lahaye, Marjolein ^l   Hargarter, Ludger ^a  

^a JANSSEN CILAG GMBH   (Germany)

^b North Estonia Medical Centre   (Estonia)

^c UNIVERSITY OF MILAN   (Italy)

^d Hospital General de Zamora   (Spain)

^e CENTRE HOSPITALIER SAINTE ANNE   (France)

^f Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

^g Welgemoed Medical Centre   (South Africa)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j Global Clinical Operations   (Poland)

^k Janssen Cilag   (France)

^l Janssen Cilag BV Netherlands   (Netherlands)

more..

Author keywords

Long acting injectable and oral antipsychotics; Paliperidone palmitate; Randomized controlled trial; Recently diagnosed; Relapse prevention; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AKATHISIA; AMENORRHEA; ANXIETY DISORDER; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FEMALE; FUNCTIONAL ASSESSMENT; GALACTORRHEA; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INJECTION SITE PAIN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE RIGIDITY; OPEN STUDY; PARKINSONISM; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RESTLESSNESS; RHINOPHARYNGITIS; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; SUICIDAL IDEATION; SYMPTOMATOLOGY; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; ADOLESCENT; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALIPERIDONE PALMITATE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84948799287     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.08.015     Document Type: Article

References (30)

1. Alphs L., Schooler N., Lauriello J. How study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophrenia. Schizophr. Res. 2014, 156(2-3):228-232.
2. Altamura A.C., Aguglia E., Bassi M., et al. Rethinking the role of long-acting atypical antipsychotics in the community setting. Int. Clin. Psychopharmacol. 2012, 27(6):336-349.
3. Atkinson M.J., Sinha A., Hass S.L., et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual. Life Outcomes 2004, 2:12.
4. Buckley P.F., Schooler N.R., Goff D.C., et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr. Bull. 2015, 41(2):449-459.
5. Csernansky J.G., Mahmoud R., Brenner R., et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002, 346(1):16-22.
6. Einarson T.R., Hemels M.E., Nuamah I., Gopal S., Coppola D., Hough D. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann. Pharmacother. 2012, 46(10):1322-1330.
7. Emsley R., Chiliza B., Asmal L., Harvey B.H. The nature of relapse in schizophrenia. BMC Psychiatry 2013, 13:50.
8. Emsley R., Chiliza B., Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr. Res. 2013, 148(1-3):117-121.
9. Emsley R., Medori R., Koen L., Oosthuizen P.P., Niehaus D.J., Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J. Clin. Psychopharmacol. 2008, 28(2):210-213.
10. EuroQol Group EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(3):199-208.
11. Fleischhacker W.W., Sanchez R., Perry P.P., et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomized, non-inferiority study. Br. J. Psychiatry 2014, 205(2):135-144.
12. Gaebel W., Schreiner A., Bergmans P., et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 2010, 35(12):2367-2377.
13. Grimaldi-Bensouda L., Rouillon F., Astruc B., et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr. Res. 2012, 134(2-3):187-194.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised 1972, US Department of Health and Human Services, Rockville, MD, DHHS publication no. ADM 91-338. (ed).
15. Janssen-Cilag International N.V. Xeplion SmPC, Accessed 8 September 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002105/WC500103317.pdf.
16. Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
17. Kane J.M., Detke H.C., Naber D., et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am. J. Psychiatry 2010, 167(2):181-189.
18. Kim B., Lee S.H., Yang Y.K., Park J.I., Chung Y.C. Long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr. Res. Treatment 2012, 2012:560836.
19. Kirson N.Y., Weiden P.J., Yermakov S., et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J. Clin. Psychiatry 2013, 74(6):568-575.
20. Kishimoto T., Nitta M., Borenstein M., Kane J.M., Correll C.U. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry 2013, 74(10):957-965.
21. Kishimoto T., Robenzadeh A., Leucht C., et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 2014, 40(1):192-213.
22. Leucht C., Heres S., Kane J.M., Kissling W., Davis J.M., Leucht S. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 2011, 127(1-3):83-92.
23. Malla A., Tibbo P., Chue P., et al. Long-acting injectable antipsychotics: recommendations for clinicians. Can. J. Psychiatry 2013, 58(5 suppl 1):30S-35S.
24. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry 1997, 58(12):538-546.
25. McEvoy J.P., Lieberman J.A., Perkins D.O., et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164(7):1050-1060.
26. Morosini P., Magliano L., Brambilla L., Ugolini S., Piolo R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
27. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(suppl 3):133-138.
28. Rosenheck R.A., Krystal J.H., Lew R., et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 2011, 364(9):842-851.
29. Ware J.E., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30(6):473-483.
30. Ware J.E., Gandek B., the IQOLA Project Group The SF-36® Health Survey: development and use in mental health research and the IQOLA Project. Int. J. Mental Health 1994, 23(2):49-73.